<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1561-3194</journal-id>
<journal-title><![CDATA[Revista de Ciencias Médicas de Pinar del Río]]></journal-title>
<abbrev-journal-title><![CDATA[Rev Ciencias Médicas]]></abbrev-journal-title>
<issn>1561-3194</issn>
<publisher>
<publisher-name><![CDATA[Editorial Ciencias Médicas]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1561-31942022000600018</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Emicizumab como tratamiento preventivo del sangrado en un paciente con hemofilia A severa]]></article-title>
<article-title xml:lang="en"><![CDATA[Emicizumab as preventive treatment of bleeding in a patient with severe hemophilia A. A case report]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Forteza-Cáceres]]></surname>
<given-names><![CDATA[Maritza]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Valdés-Sojo]]></surname>
<given-names><![CDATA[César]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Baños-Hernández]]></surname>
<given-names><![CDATA[Ihosvani]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad de Ciencias Médicas de Pinar del Río Dirección Provincial de Salud ]]></institution>
<addr-line><![CDATA[Pinar del Río ]]></addr-line>
<country>Cuba</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidad de Ciencias Médicas de Pinar del Río Hospital Pediátrico Docente Pepe Portilla ]]></institution>
<addr-line><![CDATA[Pinar del Río ]]></addr-line>
<country>Cuba</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Universidad de Ciencias Médicas de Pinar del Río Hospital Clínico Quirúrgico Docente León Cuervo Rubio ]]></institution>
<addr-line><![CDATA[Pinar del Río ]]></addr-line>
<country>Cuba</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2022</year>
</pub-date>
<volume>26</volume>
<numero>6</numero>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_arttext&amp;pid=S1561-31942022000600018&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_abstract&amp;pid=S1561-31942022000600018&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_pdf&amp;pid=S1561-31942022000600018&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  Introducción:  la hemofilia es una enfermedad hereditaria que impide la correcta coagulación de la sangre y constituye del 80 a 85 % de todas las diátesis hemorrágicas hereditarias. Es producida por la disminución de la actividad del factor VIII (hemofilia A) o del factor IX (hemofilia B).  Presentación de caso:  adolescente de 18 años de edad, de la piel blanca, atendido en el servicio de Hematología del Hospital Pediátrico Docente Pepe Portilla de Pinar del Río, que, en la etapa neonatal, presentó un hematoma a nivel de muslo derecho después de la administración de la vacuna contra hepatitis B asociado a sangrados por los sitios de puntura. A los tres meses de edad presentó su primera hemartrosis en la rodilla derecha un evento inusual en esta etapa de la vida por la escasa movilidad. A los 11 años se inició tratamiento con fisioterapia con la modalidad de hidroterapia con resultados alentadores en la recuperación del tono muscular. A inicios del año 2015, con 12 años de edad, se comenzó a utilizar el régimen de profilaxis con F VIII tres veces a la semana, que, unido a las sesiones de rehabilitación, posibilitaron la disminución de los sangrados, así como la deambulación, se incorporó de forma presencial y sin el apoyo de sillas de ruedas al escenario docente.  Conclusiones:  se concluye que el uso del emicizumab en un paciente con hemofilia A sin inhibidores, presentó un elevado perfil de seguridad, así como una alta eficiencia en la prevención de la tendencia hemorrágica.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ ABSTRACT  Introduction:  hemophilia is an inherited disease that prevents proper blood clotting and constitutes 80 to 85% of all hereditary bleeding diathesis. It is caused by decreased activity of factor VIII (hemophilia A) or factor IX (hemophilia B).  Case report:  18-year-old adolescent with white skin, attended at the Hematology Department of the Pepe Portilla Pediatric Teaching Hospital in Pinar del Río, who in the neonatal stage presented a hematoma on the right thigh after the administration of the hepatitis B vaccine associated to bleeding from the puncture sites. At 3 months of age he presented his first hemarthrosis in the right knee, an unusual event at this stage of life due to poor mobility. At 11 years of age, physiotherapy treatment was started with hydrotherapy with encouraging results in the recovery of muscle tone. At the beginning of 2015, when she was 12 years old, she began to use the prophylaxis regimen with F VIII three times a week, which together with the rehabilitation sessions, made possible the decrease of bleeding, as well as deambulation, incorporating in person and without the support of wheelchairs to the teaching scenario.  Conclusions:  it is concluded that the use of emicizumab in a patient with hemophilia A without inhibitors, presented a high safety profile, as well as a high efficiency in the prevention of bleeding tendency.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[HEMOFILIA A]]></kwd>
<kwd lng="es"><![CDATA[INHIBIDORES]]></kwd>
<kwd lng="es"><![CDATA[EMICIZUMAB]]></kwd>
<kwd lng="en"><![CDATA[HEMOPHILIA A]]></kwd>
<kwd lng="en"><![CDATA[INHIBITORS]]></kwd>
<kwd lng="en"><![CDATA[EMICIZUMAB]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rodrigo Valero]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Coagulopatías congénitas y adquiridas]]></article-title>
<source><![CDATA[NPunto]]></source>
<year>2020</year>
<volume>III</volume>
<numero>( 24</numero>
<issue>( 24</issue>
<page-range>4-22</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="book">
<source><![CDATA[Hemophilia News Today. What Is Hemophilia?]]></source>
<year>2022</year>
<publisher-name><![CDATA[BioNews]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Castillo González]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Lardoeyt Ferrer]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Almagro Vázquez]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Lam Díaz]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Lavaut Sánchez]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevalence of hemophilia in six cuban provinces.]]></article-title>
<source><![CDATA[Revista Cubana de Hematología, Inmunología y Hemoterapia]]></source>
<year>2014</year>
<volume>30</volume>
<numero>2</numero>
<issue>2</issue>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bladen]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Carroll]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Dodd]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Drechsler]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Hashem]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Patel]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Results of feasibility and safety of randomised controlled trial of a musculoskeletal exercise intervention versus usual care for children with haemophilia]]></article-title>
<source><![CDATA[Haemophilia]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Osorio]]></surname>
<given-names><![CDATA[GM]]></given-names>
</name>
<name>
<surname><![CDATA[Chávez]]></surname>
<given-names><![CDATA[SL]]></given-names>
</name>
<name>
<surname><![CDATA[Silva]]></surname>
<given-names><![CDATA[GM]]></given-names>
</name>
<name>
<surname><![CDATA[Parrello]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Iorio]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Partners of patients with a chronic disease. Narrative enquiry of hemophilia]]></article-title>
<source><![CDATA[Rev Electrónica Psicol Iztacala]]></source>
<year>2017</year>
<volume>20</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>548-69</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Osorio]]></surname>
<given-names><![CDATA[GM]]></given-names>
</name>
<name>
<surname><![CDATA[MdC]]></surname>
<given-names><![CDATA[Puente R]]></given-names>
</name>
<name>
<surname><![CDATA[Bazán R]]></surname>
<given-names><![CDATA[GE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Repercusiones físicas y sociales en la salud de portadoras que son a la vez cuidadoras primarias de pacientes con hemofilia.]]></article-title>
<source><![CDATA[Psicol y salud]]></source>
<year>2019</year>
<volume>29</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>33-40</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Oladapo]]></surname>
<given-names><![CDATA[AO]]></given-names>
</name>
<name>
<surname><![CDATA[Lu]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Walsh]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Inhibitor clinical burden of disease: a comparative analysis of the CHESS data.]]></article-title>
<source><![CDATA[Orphanet J Rare Dis]]></source>
<year>2018</year>
<volume>13</volume>
<numero>198</numero>
<issue>198</issue>
</nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Halimeh]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Ch]]></surname>
<given-names><![CDATA[Bidlingmaier]]></given-names>
</name>
<name>
<surname><![CDATA[Ch]]></surname>
<given-names><![CDATA[Heller]]></given-names>
</name>
<name>
<surname><![CDATA[Gutsche]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Holzhauer]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Kenet]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical Study Risk Factors for High-Titer Inhibitor Development in Children with Hemophilia A: Results of a Cohort Study.]]></article-title>
<source><![CDATA[BioMed Research International]]></source>
<year>2013</year>
<volume>2013</volume>
<numero>901975</numero>
<issue>901975</issue>
<page-range>2-7.</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Castillo-González]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hemofilia: aspectos históricos y genéticos]]></article-title>
<source><![CDATA[Rev. Cubana Hematol. Inmunol]]></source>
<year>2012</year>
<volume>28</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>22-33</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Boulassel]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
<name>
<surname><![CDATA[Al-Ghonimi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Al-Balushi]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Al-Naamani]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Al- Qarni]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Wali]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Regulatory B cells are functionally impaired in patients having hemophilia A with inhibitors]]></article-title>
<source><![CDATA[Clin Appl Thromb Hemost]]></source>
<year>2018</year>
<volume>24</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>618-24</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Franchini]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Mannucci]]></surname>
<given-names><![CDATA[PM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Non-factor replacement therapy for haemophilia: A current update]]></article-title>
<source><![CDATA[Blood Transfus]]></source>
<year>2018</year>
<volume>16</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>457-61</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Raut]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Heath]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<source><![CDATA[South Mimms Inhibitor Assay (SMIA): An affordable and improved method form measurement of FVIII inhibitors]]></source>
<year>2016</year>
<publisher-name><![CDATA[Presented at WFH congress]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[D]]></surname>
<given-names><![CDATA[Fantl]]></given-names>
</name>
</person-group>
<source><![CDATA[Hematología]]></source>
<year>2019</year>
<volume>22</volume>
<numero>No Extra</numero>
<issue>No Extra</issue>
<publisher-name><![CDATA[Guides 2019]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lai]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
<name>
<surname><![CDATA[Lillicrap]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Factor VIII inhibitors: Advances in basic and translational science]]></article-title>
<source><![CDATA[Int J Lab Hematol]]></source>
<year>2017</year>
<volume>39</volume>
<numero>^s1</numero>
<issue>^s1</issue>
<supplement>1</supplement>
<page-range>6-13</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Franchini]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Favaloro]]></surname>
<given-names><![CDATA[EJ]]></given-names>
</name>
<name>
<surname><![CDATA[Lippi]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mild hemophilia A]]></article-title>
<source><![CDATA[J Thromb Haemost]]></source>
<year>2010</year>
<volume>8</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>421-32.</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kitazawa]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Shima]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Emicizumab, a humanized bispecific antibody to coagulation factors IXa and X with a factor VIIIa-cofactor activity]]></article-title>
<source><![CDATA[Int J Hematol]]></source>
<year>2020</year>
<volume>111</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>20-30</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Knight]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Callaghan]]></surname>
<given-names><![CDATA[MU]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The role of emicizumab, a bispecific factor IXa- and factor X-directed antibody, for the prevention of bleeding episodes in patients with hemophilia A]]></article-title>
<source><![CDATA[Ther Adv Hematol]]></source>
<year>2018</year>
<volume>9</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>319-34</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mahlangu]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Emicizumab for the prevention of bleeds in hemophilia A]]></article-title>
<source><![CDATA[Expert Opin Biol Ther]]></source>
<year>2019</year>
<volume>19</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>753-61</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Franchini]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Marano]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Pati]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Emicizumab for the treatment of haemophilia A: a narrative review]]></article-title>
<source><![CDATA[Blood Transfus]]></source>
<year>2019</year>
<volume>17</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>223-228.</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
